|Bid||26.75 x 1300|
|Ask||29.00 x 1100|
|Day's range||27.50 - 28.24|
|52-week range||19.35 - 38.20|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||N/A|
|Earnings date||03 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||46.13|
PASADENA, Calif., March 14, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
The analysts covering Xencor, Inc. ( NASDAQ:XNCR ) delivered a dose of negativity to shareholders today, by making a...